You are here

Amgen

Amgen’s low-dose Kras curveball

EP Vantage

Thu, 04/29/21 - 10:40 am

Why Amgen's Q1 Results Disappointed Investors

Motley Fool

Wed, 04/28/21 - 10:18 am

Bristol Myers' next-gen immunology med busts Amgen's Otezla in head-to-head study. Is a showdown coming?

Endpoints

Fri, 04/23/21 - 11:12 am

Bristol Myers Squibb

deucravacitinib

The retreat of corporate venture funding?

EP Vantage

Fri, 04/23/21 - 11:02 am

venture funding

venture capital

Boehringer Ingelheim

Bristol Myers Squibb

Amgen's promising gastric cancer drug makes good on Five Prime potential with FDA's breakthrough nod

Endpoints

Tue, 04/20/21 - 11:13 am

clinical trials

Quiet times return for biopharma takeouts

EP Vantage

Wed, 04/14/21 - 09:26 am

Five Prime Therapeutics

Gilead Sciences

Horizon Therapeutics

Jazz Pharmaceutical

Anti-aging biotech upstart plucks a drug from Amgen's discard pile, pivoting from heart failure to muscle conditions

Endpoints

Wed, 04/14/21 - 09:24 am

With sales on the upswing, Amgen CEO Bradway scores a $20M pay package for 2020

Fierce Pharma

Tue, 04/6/21 - 10:57 pm

Amgen drops $55M upfront for Rodeo Therapeutics and its prostaglandin blockers

Fierce Biotech

Tue, 03/30/21 - 10:23 pm

Rodeo Therapeutics

Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies

Biopharma Reporter

Thu, 03/25/21 - 11:52 am

intellectual property

How Five Prime suitor Amgen battled multiple companies for the biotech—and won

Fierce Biotech

Fri, 03/19/21 - 10:48 am

Five Prime Therapeutics

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Fierce Biotech

Thu, 03/11/21 - 10:47 am

Mirati Therapeutics

Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal

Reuters

Thu, 03/4/21 - 10:29 am

Five Prime Therapeutics

While Life Sciences Industry Remains Strong, Some Big Names Face Layoffs

BioSpace

Tue, 03/2/21 - 12:15 pm

Gilead Sciences

AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results

BioSpace

Mon, 03/1/21 - 11:17 am

clinical trials

Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche

Fierce Biotech

Thu, 02/25/21 - 10:44 am

immune modulators

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

BioSpace

Mon, 02/22/21 - 11:49 pm

Treating COVID-19 long-haulers with Amgen's sleeper heart drug Corlanor

Fierce Biotech

Tue, 02/16/21 - 11:11 am

COVID-19 long haulers

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Endpoints

Fri, 02/12/21 - 10:48 am

Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital

Fierce Pharma

Wed, 02/3/21 - 11:28 pm

Pages